A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Trial Profile

A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Registrational; Therapeutic Use
  • Acronyms HERCULES
  • Sponsors Ablynx
  • Most Recent Events

    • 02 Oct 2017 Results from this trial are expected to support the MAA, as well as a planned Biologics License Application (BLA) filing in the United States in 2018, according to an Ablynx media release.
    • 02 Oct 2017 Primary endpoint has been met. (Time to platelet count response), according to an Ablynx media release.
    • 02 Oct 2017 Results published in an Ablynx Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top